急性冠脈綜合征患者冠脈介入治療指南ppt課件

1、Guidelines for Coronary Intervention in ACS Michael KY LeeQueen Elizabeth Hospital李耿淵李耿淵 香港伊麗莎白醫(yī)院香港伊麗莎白醫(yī)院 SCC 2021Division of CardiologyDepartment of MedicineACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/NonST-Elevation Myocardial InfarctionHospitalizations in the U.S.

2、Due to ACSAcute Coronary Syndromes*1.57 Million Hospital Admissions - ACSUA/NSTEMISTEMI1.24 million Admissions per year0.33 million Admissions per year*Primary and secondary diagnoses. About 0.57 million NSTEMI and 0.67 million UA.Heart Disease and Stroke Statistics 2007 Update. Circulation 2007; 11

3、5:69171.Primary PCI for STEMISTEMI patients presenting to a hospital with PCI capability should be treated with primary PCI within 90 min of first medical contact as a systems goal. STEMI patients presenting to a hospital without PCI capability, and who cannot be transferred to a PCI center and unde

4、rgo PCI within 90 min of first medical contact, should be treated with fibrinolytic therapy within 30 min of hospital presentation as a systems goal, unless fibrinolytic therapy is contraindicated.I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII

5、IaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII A strategy of coronary angiography with intent toperform PCI (or emergency CABG) isrecommended in patients who have receivedfibrinolytic the

6、rapy and have:Cardiogenic shock in patients 0.01 ng/mL, ST-segment deviation, TIMI risk score 3) No high-risk features, outcomes Death/MI 6 mo for older adults with early inv strategy Benefit of early inv strategy for high-risk women ( TnT); low-risk women tended to have worse outcomes, incl risk of

7、 major bleedingCannon CP, et al. N Engl J Med 2001;344:187987. Third RandomizedIntervention Treatment of Angina (RITA-3)1,810 moderate-risk ACS patientsEarly inv or conserv (ischemia-driven) strategyExclusions: CK-MB 2X ULN randomization, new Q-waves, MI w/in 1 mo, PCI w/in 1 y, any prior CABG Death

8、, MI, & refractory angina for inv strategy Benefit driven primarily by in refractory angina Death/MI 5 y for early inv armNo benefit of early inv strategy in womenFox KA, et al. Lancet 2002;360:74351. Fox KA, et al. Lancet 2005;366:91420 (5-y results).RITA-3 - 5 Year Follow-upFox KA, et al. Lanc

9、et 2005;366:91420. Reprinted with permission from Elsevier.IntracoronaryStenting with Antithrombotic Regimen Cooling-off Study (ISAR-COOL)410 patients within 24 h intermediate-high risk UA/NSTEMIVery early angio (cath median time 2.4 h) + revasc or delayed inv/“cooling off (cath median time 86 h) st

10、rategyMeds: ASA, heparin, clopidogrel (600-mg LD) and tirofiban Death/MI 30 d for early angio group Diff in outcome attributed to events that occurred before cath in the “cooling off group, which supports rationale for intensive medical rx & very early angioNeumann FJ, et al. JAMA 2003;290:15939

11、. LD = loading dose.Global Registry of Acute Coronary Events (GRACE)24,165 ACS patients in 102 hospitals in 14 countries stratified by age 2/3 men, but proportion with age Hx angina, TIA/stroke, MI, CHF, CABG, hypertension or AF in elderly (65y) Delay in seeking medical attention and NSTEMI signific

12、antly in elderly Use in elderly ASA, -blockers, lytic therapy, statins and GP IIb/IIIa inhibitors; calcium antagonists and ACE inhibitorsUFH young patients; LMWHs across all age groupsAngio and PCI rates significantly with ageElderly patients a high-risk population for whom physicians andhealthcare

13、systems should provide evidence-based ACS therapies,such as aggressive, early invasive strategy and key pharmacotherapies (e.g.anticoagulants, -blockers, clopidogrel and GP IIb/IIIa inhibitors)Avezum A, et al. Am Heart J 2005;149:6773. Initial Conservative Versus Initial Invasive StrategiesIn initia

14、lly stabilized patients, an initially conservative (i.e., a selectively invasive) strategy may be considered as a treatment strategy for UA/ NSTEMI patients (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events including those who are t

15、roponin positive. The decision to implement an initial conservative (vs. initial invasive) strategy in these patients may be made by considering physician and patient preference. An invasive strategy may be reasonable in patients with chronic renal insufficiency.I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I

16、 IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I III

17、aIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIIInvasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS)1,200 high-risk ACS patients Routine

18、 inv vs selective inv strategyMeds: ASA, clopidogrel, LMWH, and lipid-lowering rx; abciximab for revasc patientsNo death, MI, and ischemic rehosp 1 y and longer-term follow-up by routine inv strategyRelatively high (47%) rate revasc actually performed in selective inv arm and lower-risk pop than in

19、other studiesRecommendation: Initially conserv (i.e., selectively inv) strategy may be considered in initially stabilized patients who have risk for events, incl troponin + (Class IIb, LOE:B)de Winter RJ, et al. N Engl J Med 2005;353:1095104. Hirsch A, et al. Lancet 2007;369:82735 (follow-up study).

20、 LOE = level of evidence.Initial Conservative Versus Initial Invasive StrategiesAn early invasive strategy* is indicated in UA/NSTEMI patients who have refractory angina or hemodynamic or electrical instability (without serious comorbidities or contraindications to such procedures).An early invasive

21、 strategy* is indicated in initially stabilized UA/NSTEMI patients (without serious comorbidities or contraindications to such procedures) who have an elevated risk for clinical events.I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIb

22、IIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII*Diagnostic angiography with intent to perform revascularization.I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbII

23、bIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIIInitial Conservative Versus Initial Invasive StrategiesAn early invasive strategy* is not recommended in patients with extensive comorbidities (e.g., liver or pulmonary failure, cancer), in whom the risks of revascularization and comorbid conditions are lik

24、ely to outweigh the benefits of revascularization. An early invasive strategy* is not recommended in patients with acute chest pain and a low likelihood of ACS. An early invasive strategy* should not be performed in patients who will not consent to revascularization regardless of the findings. I I I

25、IIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaI

26、IaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIII*Diagnostic angiography with intent to perform revascularization.Selection of Initial Treatment Strategy: Initial Invasive Versus Conservative StrategyInvasiveInvasiveRecurrent angina/ischemia at rest with low-le

27、vel activities despite intensive medical therapyElevated cardiac biomarkers (TnT or TnI)New/presumably new ST-segment depressionSigns/symptoms of heart failure or new/worsening mitral regurgitationHigh-risk findings from noninvasive testingHemodynamic instabilitySustained ventricular tachycardiaPCI

28、within 6 monthsPrior CABGHigh risk score (e.g., TIMI, GRACE)Reduced left ventricular function (LVEF 40%)ConservativeConservativeLow risk score (e.g., TIMI, GRACE)Patient/physician presence in the absence of high-risk featuresBavry AA, et al. J Am Coll Cardiol 2006;48:13191325. Reprinted with permiss

29、ion from Elsevier. CI = confidence interval; RR = relative risk.Relative Risk of All-Cause Mortality for Early Invasive Therapy Compared With Conservative Therapy at a Mean Follow-Up of 2 yBavry AA, et al. J Am Coll Cardiol 2006; 48:13191325. CI = confidence interval; RR = relative risk. Reprinted w

30、ith permission from Elsevier.Relative Risk of Recurrent Nonfatal MI for Early Invasive Therapy Compared With Conservative Therapy at a Mean Follow-Up of 2 yRelative Risk of Recurrent UA Resulting in Rehosp for Early Invasive Therapy Compared With Conservative Therapy at a Mean Follow-Up of 13 Months

31、Bavry AA, et al. J Am Coll Cardiol 2006; 48:13191325. Reprinted with permission from Elsevier. CI = confidence interval; RR = relative risk; UA = unstable angina.Initial Invasive Strategy Efficacy and Safety ofSubcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) trial3,171 patients within

32、 24 h UA/NSTEMI Enoxaparin vs UFHOther meds: ASA Death, MI or recurrent angina for enox 14 d, 30d and 1 y minor bleeding major bleeding Cohen M, et al. N Engl J Med 1997;337:44752. Cohen M, et al. Am J Cardiol 1998;82:19L24L (bleeding). Goodman SG, et al. J Am Coll Cardiol 2000;36:69348 (1-y results

33、).Thrombolysis In Myocardial Ischemia trial, phase 11B (TIMI 11B)3,910 patients within 24 h UA/NSTEMIEnoxaparin vs UFHOther meds: ASA Death, MI or urgent revasc for enox 48 h, 8 d, 14 d, & 43 d major & minor bleeding (inhosp) with enox Antman EM, et al. Circulation 1999;100:1593601.Superior

34、Yield of the New strategy ofEnoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY)Ferguson JJ, et al. JAMA 2004;292:4554. Mahaffey KW, et al. Am Heart J 2005;149:S81S90 (6 mo & 1-y results).9,978 patients within 24 h high-risk UA/NSTEMIEnoxaparin vs UFH early inv strategyOt

35、her meds: ASA, GP IIb/IIIa physician discretionEnox noninferior for death/MI 30 d, 6 mo 1 y Major bleeding with enox ? due to crossover to UFH time of PCISYNERGY Primary OutcomesAbsolute Risk Reduction0.5Hazard Ratio0.9695% CI0.861.06p0.40Freedom from Death/MI 0.80.850.90.951.0051015202530Days from

36、RandomizationKaplan Meier CurveUFHEnoxaparinReprinted with permission from Ferguson JJ, et al. JAMA 2004;292:4554. Antithrombotic CombinationUsing Tirofiban and Enoxaparin (ACUTE II)525 patients within 24 h UA/NSTEMI Enoxaparin vs UFH Other meds: ASA, tirofiban LD 0.4 mcg/kg over 30 min 0.1 mcg/kg/m

37、inNo death/MI during first 30 d Trend to lower event rates with enoxNo major/minor bleedingCohen M, et al. Am Heart J 2002;144:4707. LD = loading dose.INTegrilin and Enoxaparin Randomized Assessment of Acute Coronary syndrome Treatment (INTERACT)746 patients within 24 h high-risk UA/NSTEMIEnoxaparin

38、 vs UFHOther meds: ASA, eptifibatide 180 mcg/kg IV bolus 2.0 mcg/kg/min infusion for 48 hours Death/MI for enox 30 d Minor bleeding - for enox 96 h, no diff by 30 dMajor bleeding - for enox 96 h (1o safety endpoint)Goodman SG, et al. Circulation 2003;107:23844.Aggrastat to Zocor (A to Z)3,987 patien

39、ts within 24 h UA/NSTEMI on ASA & tirofibanEnoxaparin vs UFH Coronary angio in 60% of ptsNo all-cause mortality, MI or refractory ischemia w/in 7 d by enox Nonsig trend to ischemic events with enox Major bleeding with enoxBlazing MA, et al. JAMA 2004;292:5564.Acute Catheterization and Urgent Int

40、erventionTriage strategY (ACUITY)Within 24 h UA/NSTEMI heparin (enox/UFH) upstream GP IIb/IIIa (n=4603) vs bivalirudin (bival) upstream GP IIb/IIIa (n=4604) vs bival alone + provisional GP IIb/IIIa (n=4612)Compared to heparin + GP IIb/IIa: Bival + GP IIb/IIIa noninferior for composite ischemia, majo

41、r bleeding & net clinical outcomes 30 d Bival alone noninferior for composite ischemia; major bleeding; net clinical outcomes 30 dCaution using bival alone, esp with delay to angio and high-risk features, or if early ischemic discomfort occurs after initial antithrombotic strategy implementedRec

42、ommend: Concomitant use of GP IIb/IIIa or thienopyridine before angio whether bival-based or heparin-based strategy usedStone GW, et al. N Engl J Med 2006;355:220311.802468101214ACUITY Compositeischemia endpoint at 30daysACUITY Major bleeding at30 daysACUITY Net clinicaloutcome at

43、 30 daysUFH or Enoxaparin + GP IIb/IIIaBivalirudin + GP IIb/IIIaACUITY Clinical Outcomes at 30 dAbsolute Risk Reduction-0.40.4-0.1Hazard Ratio1.070.931.0195% CI0.921.230.781.100.901.12p0.007* 0.001* 0.001*p for noninferiority. Stone GW, et al. N Engl J Med 2006;355:220316.ACUITY Composite Ischemia &

44、amp; Bleeding OutcomesAbsolute Risk Reduction-0.50.3-2.02.7Hazard Ratio1.080.971.290.5395% CI0.931.240.801.171.031.630.430.65p0.320.054 (for interaction) 6 h before PCIOther meds: ASA, clopidogrel, GP IIb/IIIa investigator discretionNo death, MI or refractory ischemia 9 d by fonda Noninferiority cri

45、teria met Major bleeding with fonda Death 30 d and 180 d and death, MI and stroke 180 d with fonda Catheter-assoc thrombus with fonda Yusuf S, et al. N Engl J Med 2006;354:146476. Also see Section in Anderson JL, et al. J Am Coll Cardiol 2007;50:e1-e157 for detailed discussion of trial resul

46、ts and dosing protocol.OASIS 5 Cumulative Risk of Death, MI, or Refractory Ischemia*p for noninferiority; p for superiority. Yusuf S, et al. N Engl J Med 2006;354:14649.0012345678910OASIS 5 Death, MI, or refractoryischemia at 9 daysOASIS 5 Major bleeding at 9daysOASIS 5 Composite p

47、rimaryoutcome and major bleeding at 9 daysEnoxaparinFondaparinuxAbsolute Risk Reduction-Hazard Ratio1.010.520.81Confidence Interval0.901.130.440.610.730.89p0.007* 0.001 0.001Initial Invasive Strategy:Antiplatelet TherapyFor UA/NSTEMI patients in whom an initial invasive strategy is selected

48、, it is reasonable to omit upstream administration of an intravenous GP IIb/IIIa antagonist before diagnostic angiography if bivalirudin is selected as the anticoagulant and at least 300 mg of clopidogrel was administered at least 6 h earlier than planned catheterization or PCI.I I IIIaIIaIIa IIbIIb

49、IIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIIInitial Invasive Strategy:Anticoagulant TherapyAnticoagulant therapy should be added to antiplatelet therapy in UA/NSTEMI patients as soon as possible after presentation.For patients in whom

50、 an invasive strategy is selected, regimens with established efficacy at a Level of Evidence: A include enoxaparin and unfractionated heparin (UFH) (Box B1), and those with established efficacy at a Level of Evidence: B include bivalirudin and fondaparinux (Box B1).I I IIIaIIaIIa IIbIIbIIb IIIIIIIII

51、I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIIClopidogrel in Unstable angina to preventRecurrent ischemic Events (CURE

52、)12,562 patients within 24 h UA/NSTEMIPlacebo vs clopidogrel (LD 300 mg 75 mg qd)Other meds: ASA CV death, MI, or stroke, rate of recurrent ischemia & revasc with clopidogrel Major (nonlife-threatening) bleeding with clopidogrelNo routine inv strategy, 23% revasc during initial admissionAlthough

53、 well tolerated, 50% diameter stenosis) who are candidates for revascularization but are not eligible for CABG or who require emergent intervention at angiography for hemodynamic instability.PCI is reasonable for UA/NSTEMI patients with diabetes mellitus with single-vessel disease and inducible isch

54、emia.I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIII

55、II I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIIRecommendations for PCI in Patients With UA/NSTEMIIn the absence of high-risk features associated with UA/NSTEMI, PCI may be considered in patients with single-vessel or multivessel CAD who are undergoi

56、ng medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. PCI may be considered for UA/NSTEMI patients who are undergoing medical therapy who have 2- or 3-vessel disease, significant proximal LAD CAD, and treated diabetes or abnormal LV function, with anat

57、omy suitable for catheter-based therapy. I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIII

58、IIIRecommendations for PCI in Patients With UA/NSTEMIPCI (or CABG) is not recommended for patients with 1- or 2-vessel CAD without significant proximal LAD CAD with no current symptoms or symptoms that are unlikely to be due to myocardial ischemia and who have no ischemia on noninvasive testing. A P

59、CI strategy in stable patients with persistently occluded infarct-related coronary arteries after NSTEMI is not indicated.I I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIII I IIIaIIaII

60、a IIbIIbIIb IIIIIIIIII I IIIaIIaIIa IIbIIbIIb IIIIIIIIIIIaIIaIIa IIbIIbIIb IIIIIIIIIRecommendations for PCI in Patients With UA/NSTEMIIn the absence of high-risk features associated with UA/NSTEMI, PCI is not recommended for patients with UA/NSTEMI who have single-vessel or multivessel CAD and no trial of medical therapy, or who ha